Results 141 to 150 of about 52,382 (294)

Patients’ needs in hematology: whose perspectives?

Haematologica, 2013
Sam Salek, Tatyana Ionova, Esther Oliva
doaj   +1 more source

Challenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023–2024 Outbreak in Argentina

Transplant Infectious Disease, EarlyView.
During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez, Carla Niveyro, Pedro Andrés Villalba Apestegui, Victoria Isabel Martin, Lucila María Compañy Kec, María Cynthia Tomasino, Mariana del Carmen del Marull, Haydee Ingrid Bernard, Claudia Patricia Lorena Fernández, Flavia Marcela Pelech, Maria Fernanda Tosin, María Fernanda González‐Hobecker, Karen Beatrice Duranona, Angela Daiana Jara, Justus Cornely, Oliver A. Cornely, Jon Salmanton‐García   +16 more
wiley   +1 more source

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Transfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone‐Junior, José Bordin, Langhi Dante, Carla Dinardo   +11 more
wiley   +1 more source

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumas, Karen M. K. de Vooght, Jill R. Storry, Jennylyn Flores, Núria Nogués, Carlos Cotorruelo, Molly Rutherford, Eveline B. Nilsen, Monika Pelc‐Kłopotowska, Jolanta Korzeniowska, Alessandra Baffa, Inna Sareneva, Nor Hafizah Ahmad, Katarzyna Szczudlo, Athif Rahman, Laser Sanal, Lise Jørgensen, Karolina Majewska Rochowiak, Monika Salwierz, Elisaveta Grancharova, Bojana Zivkovic, Jessica Alvarez, Mareike Riedl, Achim Knappik   +30 more
wiley   +1 more source

Cognitive Functioning in Vorinostat‐Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Purpose Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success.
Kristen L. Votruba, Michelle Rozwadowski, Thomas Braun, April Rahrig, Edward Peres, Kirsten M. Williams, Vanessa Fabrizio, Julie‐An Talano, Carrie L. Kitko, Nicolas Parnell, Pavan Reddy, Sung Won Choi   +11 more
wiley   +1 more source

Distinct Pattern of Atypical Megakaryocytes in VEXAS Syndrome

International Journal of Laboratory Hematology, EarlyView.
Andrew Y. Sung, Jackson W. Douglas, Olga K. Weinberg, Sharon K. Germans, Weina Chen   +4 more
wiley   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen [PDF]

, 2017
Abboud, Camille N, Ali, Alaa M, Cashen, Amanda F, DiPersio, John F, Fehniger, Todd A, Gao, Feng, Ghobadi, Armin, Jacoby, Meagan A, Oh, Stephen T, Pusic, Iskra, Romee, Rizwan, Schroeder, Mark A, Stockerl-Goldstein, Keith E, Uy, Geoffrey L, Vij, Ravi, Wartman, Lukas D, Weisel, Daniel, Welch, John S, Westervelt, Peter   +18 more
core   +2 more sources

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Myelodysplastic syndromes

HemaSphere, 2018
Eva Hellström Lindberg
doaj   +1 more source